O3–01–08: Adiponectin decrease may conditionate the onset of pathogenetic phenotype of metabolic syndrome and insulin resistance in subjects with Alzheimer's disease

spinal fluid (CSF) biomarkers -amyloid peptide (A 1-42), total tau protein (tau) and tau phosphorylated at threonine 181 (P-tau181P) remains to be established compared to clinical diagnosis in autopsyconfirmed dementia subjects. Methods: A total of 100 CSF samples from demented patients with autopsy-confirmed pathological diagnoses were included. CSF levels of A 1-42, tau and P-tau181P were determined with commercially available single parameter ELISA kits (INNOTEST®). Results: Diagnostic accuracy of a biomarker model (using age-corrected CSF levels of A 1-42 and P-tau181P) differentiating Alzheimer’s disease (AD) from other dementias was 82.7% compared to 81.6% for clinical diagnosis, showing that this biomarker model gives the same information as a whole clinical work-up (including imaging). Using the biomarker-based model in cases with clinically doubtful diagnoses, a correct diagnosis would have been established in 4 of the 6 autopsy-confirmed AD cases and 3 of the 3 autopsy-confirmed cases with other dementias. Conclusions: This study showed the value of biomarkers in differential dementia diagnosis, using the gold standard (pathological diagnosis) as a reference. Diagnostic accuracy of a biomarker-based model is comparable to clinical diagnostic accuracy, and can help in establishing a correct diagnosis in case of doubtful clinical diagnoses.